Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

by · The Cerbat Gem

HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $7.50.

Read Our Latest Analysis on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Stock Up 5.0 %

LXRX opened at $1.69 on Thursday. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73. The firm has a market capitalization of $416.14 million, a P/E ratio of -2.04 and a beta of 1.28. The company’s 50-day moving average is $1.70 and its 200 day moving average is $1.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $2.74 million. During the same quarter last year, the business posted ($0.22) EPS. Research analysts expect that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL increased its stake in shares of Lexicon Pharmaceuticals by 22.2% during the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after purchasing an additional 4,440,300 shares during the last quarter. Vanguard Group Inc. increased its position in Lexicon Pharmaceuticals by 7.0% in the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock worth $15,363,000 after buying an additional 420,854 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Lexicon Pharmaceuticals by 605.2% in the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after buying an additional 3,536,805 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at $3,871,000. Finally, Pinnacle Associates Ltd. lifted its position in shares of Lexicon Pharmaceuticals by 1.0% during the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company’s stock valued at $4,195,000 after buying an additional 17,009 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

Read More